Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus

Journal of Viral Hepatitis

Volumn 9, Issue 2, 2002, Pages 107-113

  Rivero, Montserrat ^a   Crespo, J ^a   Fabrega E ^a   Casafont, F ^a   Mayorga, M ^a   Gomez Fleitas, M ^a   Pons Romero, F ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Apoptosis; Fas antigen; Fulminant hepatitis; Hepatitis B virus; Soluble serum Fas; TUNEL

Indexed keywords

FAS ANTIGEN; VIRUS DNA;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CASE REPORT; CELL NUCLEUS; CONTROLLED STUDY; DNA DETERMINATION; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL; LYMPHOCYTIC INFILTRATION; MALE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; VIRUS GENE;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIGENS, CD95; APOPTOSIS; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; IN SITU NICK-END LABELING; LIVER FAILURE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; SOLUBILITY;

EID: 0036904115     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00338.x     Document Type: Article

References (27)

1. Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 99: 2333-2343.
2. Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effects of the anti-Fas antibody in mice. Nature 1996; 364: 806-809.
3. Mochizuki K, Hayashi N, Hiramatsu N et al. Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 1996; 24: 1-7.
4. Luo KX, Zhu YF, Zhang LX, He HT, Wang XS, Zhang L. In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases. J Viral Hepat 1997; 4: 303-307.
5. Galle PR, Hofmann WJ, Walczak H et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-1230.
6. Kosaka Y, Takase K, Kojima M et al. Fulminant hepatitis B. Induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology 1991; 100: 1087-1094.
7. Hasegawa K, Huang J, Wands JR, Obata H, Liang J. Association of hepatitis B viral precore mutations with fulminant hepatitis B in Japan. Virology 1991; 185: 460-463.
8. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324: 1699-1704.
9. Sterneck M, Kalinina T, Günther S et al. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology 1998; 28: 1390-1397.
10. Sterneck M, Guenther S, Santantonio T et al. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology 1996; 24: 300-306.
11. Trey C, Davidson CS. The Management of Fulminant Hepatic Failure. In: Popper, H, Schaffner, F, eds. Progress in Liver Failure. 1970: 292-298.
12. Crespo J, Fábrega E, Casafont F et al. Severe course of de novo hepatitis B after liver transplantation. Liv Transplant Surg 1999; 5: 1-9.
13. Sanger F, Nicken S, Coulson AR. DNA sequencing chain-termination inhibitor. Proc Natl Acad Sci, 1977; 74: 5447-5457.
14. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
15. Hayashi N, Mita E. Fas system and apoptosis in viral hepatitis. J Gastroenterol Hepatol 1997; 12: 223-226.
16. Ryo K, Kamogawa Y, Ikeda I et al. Significance of Fas antigen-medietad apoptosis in fulminant hepatic failure. Am J Gastroenterol 2000; 95: 2048-2055.
17. Crespo J, Rivero M, Mayorga M et al. Involvement of the Fas System in hepatitis C virus recurrence after liver transplantation. Liver Transplantation. 2000; 6: 562-569.
18. Okazaki M, Hino K, Fujii K, Kobayashi N, Okita K. Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 2453-58.
19. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kamada T. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-1359.
20. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bokowsk K, Bursch W, Schulte-Hermann R. In situ detection of fragmental DNA (TUNEL Assay) fails to discriminate among apoptosis, necrosis an autolytic cell death: A cautionary note. Hepatology 1995; 5: 1465-1468.
21. Arends MJ, Wyllie AH. Apoptosis: Mechanisms and roles in pathology. Int Rev Exp Pathol 1991; 32: 223-254.
22. Cheng J, Zhou T, Liu C et al. Protection from Fas mediated apoptosis by soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
23. Iio S, Hayashi N, Mita E et al. Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 1998; 29: 517-523.
24. Toyoda M, Kakizaki S, Horiguchi N et al. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. Liver 2000; 20: 305-311.
25. Rivero M, Crespo J, Mayorga M et al. Involvement of the Fas system in liver allograft rejection. Hepatology 1999; 28: 180.
26. Terradillos O, Pollicino T, Lecoeur H et al. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998; 17: 2115-2123.
27. Gottlob K, Fulco M, Levrero M, Graessmann A. The hepatitis B virus HBx protein inhibits caspase 3 activity. J Biol Chem 1998; 273: 33347-33353.